LOGO

Checklist: Hope For Parkinson's Patients

Acadia Pharmaceuticals sets its sights on a little-known side of the disease.
Posted on Sep 22, 2021 | 02:30pm
Brought to you by Watch!

If you're a caregiver to one of the roughly one million people in the US alone who suffers from Parkinson's Disease, you're probably aware of its physical symptoms—tremors, muscle stiffness, difficulty with speech and movement. But not every caregiver knows that at least 40 percent of sufferers are also afflicted with Parkinson's disease psychosis, which manifests itself in delusions and hallucinations, as well as paranoia.

While many traditional antipsychotic drugs interact with the brain chemicals serotonin and dopamine, Acadia's NUPLAZID (pimavanserin) is the first antipsychotic to target serotonin alone, making it less likely to affect motor symptoms or interfere with the movement-regulating drugs a Parkinson's patient may already be taking. As the only US FDA-approved drug for treating Parkinson's disease psychosis, NUPLAZID has been shown to improve symptoms in as little as two weeks, though it may take six weeks for patients to feel its full effect.

If you think NUPLAZID might benefit someone you know, talk to their doctor. For product information, prescribing information, medication guide, and possible side effects, visit nuplazid.com.

Photo Credit: Ridofranz/Getty Images.